NASDAQ · Biotechnology

Cibus, Inc. (CBUS) Stock

$1.41 +0.71% NASDAQ: CBUS Healthcare

Valuation

MetricValue
Price$1.41
Market Cap$107.76M
P/E Ratio-1.04
P/B Ratio8.87
P/S Ratio30.03
EPS (TTM)$0.00
52-Week High$4.19
52-Week Low$1.09
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-320.60%
ROA-31.33%
ROCE-18.04%
Gross Margin-1675.00%
Operating Margin-1675.00%
Net Margin-23.66%
Debt/Equity2.21
Current Ratio0.71

Annual Financials (USD)

Metric20212022202320242025
Revenue$26.0M$0$2.0M$4.0M$4.0M
Operating Profit$-29.0M$-22.0M$-319.0M$-77.0M$-67.0M
Net Profit$-29.0M$-17.0M$-268.0M$-251.0M$-127.0M
EPS$-38.96$-18.36$-25.95$-10.83$-2.78
Op Margin-112.9%-14248.4%-17550.0%-1805.8%-1853.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$37.0M$22.0M$544.0M$350.0M$305.0M
Total Liabilities$23.0M$15.0M$206.0M$252.0M$283.0M
Cash$14.0M$3.0M$33.0M$14.0M$10.0M
Borrowings$18.0M$14.0M$25.0M$36.0M$268.0M

Latest News

Cibus (CBUS) Welcomes Landmark EU Crop Breeding Decision Insider Monkey · Jul 14, 2026 Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus GlobeNewswire · Jun 17, 2026 Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation GlobeNewswire · Jun 8, 2026 Cibus, Inc. Q1 2026 Earnings Call Summary Moby · May 15, 2026 Cibus Inc (CBUS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges GuruFocus.com · May 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-19.0M$-46.0M$-58.0M$-51.0M
Investing Cash Flow$11.0M$-3.0M$51.0M$-2.0M$-1.0M
Financing Cash Flow$-1.0M$-1.0M$2.0M$-2.0M$0
Net Cash Flow$-4.0M$-11.0M$29.0M$-18.0M$-5.0M
Free Cash Flow$-19.0M$-21.0M$-51.0M$-59.0M$-51.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-2.42
FCF Yield-35.49%
Quick Ratio1.62
Interest Coverage-2.87
Return 1Y42.36%
Return 3Y-89.11%
Return 5Y-98.90%

Ownership

Insiders Held26.13%
Institutions Held33.63%
Institutions Float Held45.52%
Institutional HolderSharesReport Date
FMR, LLC11,425,9292026-03-31
Vanguard Capital Management LLC2,118,4962026-03-31
Davidson Kempner Capital Management LP1,527,6062026-03-31
Vantage Consulting Group, Inc1,143,9492025-12-31
Weiss Asset Management Lp888,1242026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRVAcrivon Therapeutics, Inc. $1.73 -1.70% -1.12 $74.14M 0.00%
BMEABiomea Fusion, Inc. $0.60 +2.58% -2.56 $43.39M 0.00%
CAMPCAMP4 Therapeutics Corporation $3.30 -2.65% -1.55 $207.09M 0.00%
IMUXImmunic, Inc. $7.41 +2.63% -1.39 $101.11M 0.00%
MNOVMediciNova, Inc. $1.39 -1.42% -8.20 $68.42M 0.00%

About Cibus, Inc.

Cibus, Inc. is led by CEO Peter R. Beetham, employs 157 people, headquartered in US, publicly traded since 2017.

Cibus, Inc. (CBUS) stock trades at $1.41 with a market capitalization of $107.76M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.04, reflecting a net loss over the last twelve months, price-to-book of 8.87, price-to-sales of 30.03. Over the past 52 weeks the stock has ranged between $1.09 and $4.19, and currently trades 66.4% below its 52-week high.

On profitability, Cibus, Inc. generates a return on equity (ROE) of -320.60% (negative, reflecting a net loss), return on capital employed of -18.04%, an operating margin of -1675.00%, a net profit margin of -23.66%.

Cibus, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Cibus, Inc. reported revenue of $0 rising to $4.0M. Compounded, revenue has grown -30.1% a year over five years, —% over three, 0.0% over the last twelve months. Net profit fell to $-127.0M.

Operating margin went from -3034.8% in 2016 to -1853.9% in 2025, a gain of 1180.9 percentage points. The most recent net margin is -23.66%. On a trailing twelve-month basis to Jun '26, revenue is $5.0M and net profit $-98.0M.

Borrowings stand at $268.0M, cash from operations was $-51.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -278.3% over five years, and was -577.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Cibus, Inc. (CBUS) — frequently asked questions

What is Cibus, Inc. (CBUS) stock price today?

Cibus, Inc. (CBUS) is currently trading at $1.41, up 0.71% today.

What is CBUS P/E ratio?

Cibus, Inc.'s P/E ratio is -1.04. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is CBUS return on equity (ROE)?

Cibus, Inc.'s return on equity (ROE) is -320.60%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Cibus, Inc.'s market cap?

Cibus, Inc. has a market capitalization of $107.76M.

Does CBUS pay a dividend?

Cibus, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does CBUS carry?

Cibus, Inc. has a debt-to-equity ratio of 2.21. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is CBUS's profit margin?

Cibus, Inc. reports a net profit margin of -23.66% — the share of revenue left after every cost, including tax and interest.

What sector is CBUS in?

Cibus, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is CBUS listed on?

Cibus, Inc. trades on NASDAQ under the ticker CBUS.

What is CBUS's 52-week range?

Over the last year Cibus, Inc. has traded between $1.09 and $4.19.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens CBUS currently matches

On the figures above, Cibus, Inc. passes the filters for 3 of our ready-made screens, among them Penny Stocks, Stocks Under $5, Micro Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Penny StocksStocks Under $5Micro Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.